Innoblative Announces Successful First-in-Human Use of its Novel Electrosurgical Device for Breast Cancer Treatment
- The company’s SIRA® RFA Electrosurgical Device designed specifically for patients undergoing breast-conserving surgery (BCS)
- Breast cancer is the second most common cancer worldwide with over 2.3M new cases each year
CHICAGO, July 16, 2024 /PRNewswire/ — Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has initiated its first-in-human clinical experience, successfully treating a 64-year-old patient with stage II luminal A breast cancer. The initial lumpectomy case was performed by Dr. Cem Yilmaz, Breast Surgeon and Founding Director of the Istanbul Oncology Hospital in Istanbul, Turkey.
